Mepolizumab
- Generic Name
- Mepolizumab
- Brand Names
- Nucala
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 196078-29-2
- Unique Ingredient Identifier
- 90Z2UF0E52
- Background
Eosinophils are involved in inflammatory immune responses, and prolonged hypereosinophilia (typically defined as absolute eosinophil levels of 1500/mm or more) is associated with a spectrum of diseases, including severe asthma, eosinophilic granulomatosis with polyangiitis (EGPA), and hypereosinophilic syndrome (HES). The pathogenesis of eosinophilia is comp...
- Indication
Mepolizumab is an anti-IL-5 IgG1 kappa monoclonal antibody indicated as an add-on maintenance treatment in patients aged six years and older with severe eosinophilic asthma and as a treatment in adult patients for eosinophilic granulomatosis with polyangiitis (EGPA). Mepolizumab is also indicated for the treatment of hypereosinophilic syndrome (HES) in patie...
- Associated Conditions
- Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP), Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) (EGPA), Hypereosinophilic Syndrome (HES), Severe Eosinophilic Asthma
- Associated Therapies
- -
Response and Remission to Treatment With Anti-IL5/IL5R Antagonists
- Conditions
- First Posted Date
- 2024-04-04
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- Université de Montréal
- Target Recruit Count
- 109
- Registration Number
- NCT06348173
- Locations
- 🇨🇦
Hôpital du Sacré-Coeur de Montréal, Montréal, Quebec, Canada
th2 Modulation CRSwNP
- Conditions
- Interventions
- First Posted Date
- 2023-10-30
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- St. Paul's Sinus Centre
- Target Recruit Count
- 40
- Registration Number
- NCT06107101
- Locations
- 🇨🇦
St. Paul's Sinus Centre, Vancouver, British Columbia, Canada
REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study
- First Posted Date
- 2023-09-18
- Last Posted Date
- 2023-09-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 336
- Registration Number
- NCT06041386
Mepolizumab and In-office Nasal Polypectomy in Patients With Chronic Rhinosinusitis (CRS). A Three Arm Study.
- Conditions
- Interventions
- First Posted Date
- 2023-06-28
- Last Posted Date
- 2023-06-28
- Lead Sponsor
- Instituto de Investigación Marqués de Valdecilla
- Target Recruit Count
- 75
- Registration Number
- NCT05923047
- Locations
- 🇪🇸
Hospital de Curces, Bilbao, Spain
🇪🇸Hospital de Jerez, Jerez De La Frontera, Spain
🇪🇸HUCA, Oviedo, Spain
The Role of IL5 in Epithelial Cell Integrity
- Conditions
- Interventions
- First Posted Date
- 2023-06-09
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 8
- Registration Number
- NCT05895929
- Locations
- 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States
Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)
- Conditions
- Interventions
- First Posted Date
- 2022-03-03
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 160
- Registration Number
- NCT05263934
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Study for Children & Adolescent With Severe Asthma With an Eosinophilic Phenotype Treated With Mepolizumab
- First Posted Date
- 2021-12-01
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- King's College Hospital NHS Trust
- Target Recruit Count
- 148
- Registration Number
- NCT05139381
- Locations
- 🇬🇧
King's College Hospital, London, United Kingdom
Treatment With Mepolizumab on Patients With Severe Refractory Eosinophilic Asthma With or Without CRSwNP.
- First Posted Date
- 2021-10-01
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- Istituti Clinici Scientifici Maugeri SpA
- Target Recruit Count
- 20
- Registration Number
- NCT05063981
- Locations
- 🇮🇹
Istituti Clinici Scientifici Maugeri IRCCS, Telese Terme, BN, Italy
Study of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients with Eosinophilic Granulomatosis with Polyangiitis (E-merge)
- Conditions
- Interventions
- First Posted Date
- 2021-09-01
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 100
- Registration Number
- NCT05030155
- Locations
- 🇫🇷
Service de Médecine Interne, Centre de référence " Maladies systémiques et autoimmunes rares, en particulier Vascularites nécrosantes et Sclérodermies systémiques "Hôpital Cochin, Paris, France
Study in Pediatrics With HypEREosinophilic Syndrome (SPHERE)
- First Posted Date
- 2021-07-16
- Last Posted Date
- 2023-08-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 25
- Registration Number
- NCT04965636
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.